Thumbnail
Access Restriction
Open

Author Patrick, Chames ♦ Van Regenmortel, Marc ♦ Weiss, Etienne ♦ Baty, Daniel
Source PubMed Central
Content type Text
Publisher Blackwell Publishing Ltd
File Format PDF
Date Created 2009-04-28
Language English
Difficulty Level Medium
Subject Domain (in DDC) Technology ♦ Medicine & health
Subject Keyword Pharmacology
Abstract With more than 20 molecules in clinical use, monoclonal antibodies have finally come of age as therapeutics, generating a market value of $11 billion in 2004, expected to reach $26 billion by 2010. While delivering interesting results in the treatment of several major diseases including autoimmune, cardiovascular and infectious diseases, cancer and inflammation, clinical trials and research are generating a wealth of useful information, for instance about associations of clinical responses with Fc receptor polymorphisms and the infiltration and recruitment of effector cells into targeted tissues. Some functional limitations of therapeutic antibodies have come to light such as inadequate pharmacokinetics and tissue accessibility as well as impaired interactions with the immune system, and these deficiencies point to areas where additional research is needed. This review aims at giving an overview of the current state of the art and describes the most promising avenues that are being followed to create the next generation of antibody-based therapeutic agents.
ISSN 00071188
Age Range above 22 year
Educational Use Research
Interactivity Type Expositive
Education Level UG and PG
Learning Resource Type Article
Publisher Date 2009-04-01
Rights Holder Blackwell Publishing Ltd
e-ISSN 14765381
Journal British Journal of Pharmacology
Volume Number 157
Issue Number 2
Page Count 14
Starting Page 220
Ending Page 233


Open content in new tab

   Open content in new tab
Source: PubMed Central